Once-daily tobramycin in cystic fibrosis: Better for clinical outcome than thrice-daily tobramycin but more resistance development?

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 4, 2006, Pages 822-829

  Burkhardt, Olaf ^a,b   Lehmann, Christine ^a   Madabushi, Rajanikanth ^b   Kumar, Vipul ^b   Derendorf, Hartmut ^b   Welte, Tobias ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Lung function; PK PD; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; CEFTAZIDIME; IMMUNOGLOBULIN G; MEROPENEM; TOBRAMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GRAM NEGATIVE INFECTION; HUMAN; LEUKOCYTE COUNT; LINEAR SYSTEM; LIVER TOXICITY; LUNG FUNCTION; LUNG INFECTION; MALE; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; OPTIMAL DRUG DOSE; OTOTOXICITY; PHARMACODYNAMICS; PREDICTION; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VITAL CAPACITY;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 33748695978     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl328     Document Type: Article

References (57)

1. Hoiby N. Microbiology of cystic fibrosis. In: Hodson ME, Geddes DM, eds. Cystic Fibrosis. London: Chapman and Hall Medical, 1995; 75-98.
2. Hoiby N. Antibiotic therapy for chronic infection of Pseudomonas in the lung. Annu Rev Med 1993; 44: 1-10.
3. Mouton JW, Kerrebijn KF. Antibacterial therapy in cystic fibrosis. Med Clin North Am 1990; 74: 837-50.
4. Brewer NS. Antimicrobial agents - Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin. Mayo Clin Proc 1977; 52: 675-9.
5. Lacy MK, Nicolau DP, Nightingale CH et al. The pharmacodynamics of aminoglycosides. Clin Infect Dis 1998; 27: 23-7.
6. Kim MK, Nicolau DP. Aminoglycoside pharmacodynamics. In: Nightingale C, Marakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel-Dekker, 2002; 125-53.
7. Craig WA. Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale C, Marakawa T, Ambrose PG, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice. New York: Marcel-Dekker, 2002; 1-22.
8. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-62.
9. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443-8.
10. Nicolau DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
11. Kapusnik JE, Hackbarth CJ, Chambers HF et al. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia. J Infect Dis 1988; 158: 7-12.
12. Zhanel GG, Ariano RE. Once daily aminoglycoside dosing: Maintained efficacy with reduced nephrotoxicity?. Ren Fail 1992; 14: 1-9.
13. Prins JM, Buller HR, Kuijper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
14. Wood PJ, Ioannides-Demos LL, Li SC et al. Minimisation of aminoglycoside toxicity in patients with cystic fibrosis. Thorax 1996; 51: 369-73.
15. Rybak MJ, Abate BJ, Kang SL et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
16. Smyth A, Tan KH, Hyman-Taylor P et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: A randomised controlled trial. Lancet 2005; 365: 573-8.
17. Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualization. Clin Pharmacokinet 1999; 37: 289-304.
18. Schuck EL, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 2005; 3: 361-73.
19. Forrest A, Nix DE, Ballow CH et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
20. Ambrose PG, Grasela DM, Grasela TH et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-7.
21. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother 2003; 37: 1287-98.
22. Schentag JJ, Meagher AK, Forrest A. Fluoroquinolone AUIC breakpoints and the link to bacterial killing rates. Part 2: Human trials. Ann Pharmacother 2003; 37: 1478-88.
23. Bastone EB, Li SC, Ioannides-Demos LL et al. Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing. Antimicrob Agents Chemother 1993; 37: 914-7.
24. Rayner CR, Ioannides-Demos LL, Brien JA et al. Initial concentration-time profile of gentamicin determines efficacy against Enterobacter cloacae ATCC 13047. Antimicrob Agents Chemother 1998; 42: 1370-4.
25. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
26. Kashuba AD, Nafzinger AN, Drusano GL et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9.
27. Smith P, Ballow CH, Booker BM et al. Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther 2001; 23: 1231-44.
28. Mouton JW, Jacobs N, Tiddens H et al. Pharmacodynamics of tobramycin in patients with cystic fibrosis. Diagn Microbiol Infect Dis 2005; 52: 123-7.
29. Horrevorts AM, Degener JE, Dzoljic-Danilovic G et al. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval. Chest 1985; 88: 260-4.
30. Horrevorts AM, de Witte J, Degener JE et al. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment. Chest 1987; 92: 844-8.
31. Jonsson EN, Karlsson MO. Xposean S-PLUS based population pharmacokinetic/ pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
32. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic models. In: D'Argenio DZ, ed. Advanced Methods of Pharmacokinetic and Pharmacodynamic System Analysis. New York: Plenum Press, 1995; 69.
33. Tamasiro L. Broth microdilution MIC testing. In: Isenberg HD, ed. Clinical Microbiology Procedures Handbook. Washington, DC: American Society for Microbiology, 1992.
34. Winter ME. Basic Clinical Pharmacokinetics. Philadelphia: Lippincott Williams and Wilkins, 2004; 132-3.
35. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22: 364-70.
36. Schentag JJ, Jusko WJ, Plaut ME et al. Tissue persistence of gentamicin in man. JAMA 1977; 238: 327-9.
37. Ratjen F, Doring G. Cystic fibrosis. Lancet 2003; 361: 681-9.
38. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
39. Emerson J, Rosenfeld M, McNamara S et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
40. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: Pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003; 9: 492-7.
41. Canton R, Cobos N, de Gracia J et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11: 690-703.
42. Powell SH, Thompson WL, Luthe MA et al. Once-daily vs. continuous aminoglycoside dosing: Efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983; 147: 918-32.
43. Vic P, Ategbo S, Turck D et al. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis. Arch Dis Child 1998; 78: 536-9.
44. Bragonier R, Brown NM. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis. J Antimicrob Chemother 1998; 42: 103-6.
45. Whitehead A, Conway SP, Etherington C et al. Once-daily tobramycin in the treatment of adult patients with cystic fibrosis. Eur Respir J 2002; 19: 303-9.
46. Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin. Study Group. N Engl J Med 1999; 340: 23-30.
47. Touw DJ. Clinical pharmacokinetics of antimicrobial drugs in cystic fibrosis. Pharm World Sci 1998; 20: 149-60.
48. Al-Aloul M, Crawley J, Winstanley C et al. Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients. Thorax 2004; 59: 334-6.
49. Mouton JW, den Hollander JG, Horrevorts AM. Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Antimicrob Chemother 1993; 31: 919-26.
50. Ciofu O, Giwercman B, Pedersen SS et al. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS 1994; 102: 674-80.
51. Taccetti G, Campana S, Marianelli L. Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: The results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Eur J Epidemiol 1999; 15: 85-8.
52. Spencker FB, Staber L, Lietz T et al. Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times. Clin Microbiol Infect 2003; 9: 370-9.
53. Karlowsky JA, Saunders MH, Harding GA et al. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 1387-93.
54. Karlowsky JA, Zelenitsky SA, Zhanel GG. Aminoglycoside adaptive resistance. Pharmacotherapy 1997; 17: 549-55.
55. Whiteley M, Bangera MG, Bumgarner RE et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001; 413: 860-4.
56. Mah TF, Pitts B, Pellock B et al. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 2003; 426: 306-10.
57. Hoffman LR, D'Argenio DA, MacCoss MJ et al. Aminoglycoside antibiotics induce bacterial biofilm formation. Nature 2005; 436: 1171-5.